Formation Bio Raises $600M to Buy Stalled Drug Programs and Run Them With AI
The AI-native pharma company launched a $600M fund to acquire 10–15 Phase 1–2 clinical assets, signaling AI's move out of drug discovery and into full clinical development.
Formation Bio launched a $600M AI Drug Development Accelerator Fund this week, with a specific and unusual mandate: acquire and advance 10 to 15 clinical-stage drug programs stuck in Phase 1 or Phase 2. As reported by @BREC_Solutions, the fund is structured to buy assets and push them forward, not to discover new molecules. That distinction matters enormously.
Unlock the full briefing
Get every story in today's briefing, the full archive, and the daily AI intelligence brief.
All stories today
Full archive
Daily brief
Cancel anytime. Payments powered by Stripe.